AXL kinase as a novel target for cancer therapy

Xiaoliang Wu, Xuewen Liu, Sanjay Koul, Chang Youl Lee, Zhenfeng Zhang, Balazs Halmos

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

The AXL receptor tyrosine kinase and its major ligand, GAS6 have been demonstrated to be overexpressed and activated in many human cancers (such as lung, breast, and pancreatic cancer) and have been correlated with poor prognosis, promotion of increased invasiveness/metastasis, the EMT phenotype and drug resistance. Targeting AXL in different model systems with specific small molecule kinase inhibitors or antibodies alone or in combination with other drugs can lead to inactivation of AXL-mediated signaling pathways and can lead to regained drug sensitivity and improved therapeutic efficacy, defining AXL as a promising novel target for cancer therapeutics. This review highlights the data supporting AXL as a novel treatment candidate in a variety of cancers as well as the current status of drug development targeting the AXL/GAS6 axis and future perspectives in this emerging field.

Original languageEnglish (US)
Pages (from-to)9546-9563
Number of pages18
JournalOncotarget
Volume5
Issue number20
StatePublished - 2014
Externally publishedYes

Fingerprint

Phosphotransferases
Neoplasms
Receptor Protein-Tyrosine Kinases
Drug Delivery Systems
Pancreatic Neoplasms
Drug Resistance
Pharmaceutical Preparations
Lung Neoplasms
Therapeutics
Breast Neoplasms
Neoplasm Metastasis
Ligands
Phenotype
Antibodies

Keywords

  • Axl
  • Lung cancer
  • Receptor tyrosine kinase
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Wu, X., Liu, X., Koul, S., Lee, C. Y., Zhang, Z., & Halmos, B. (2014). AXL kinase as a novel target for cancer therapy. Oncotarget, 5(20), 9546-9563.

AXL kinase as a novel target for cancer therapy. / Wu, Xiaoliang; Liu, Xuewen; Koul, Sanjay; Lee, Chang Youl; Zhang, Zhenfeng; Halmos, Balazs.

In: Oncotarget, Vol. 5, No. 20, 2014, p. 9546-9563.

Research output: Contribution to journalArticle

Wu, X, Liu, X, Koul, S, Lee, CY, Zhang, Z & Halmos, B 2014, 'AXL kinase as a novel target for cancer therapy', Oncotarget, vol. 5, no. 20, pp. 9546-9563.
Wu X, Liu X, Koul S, Lee CY, Zhang Z, Halmos B. AXL kinase as a novel target for cancer therapy. Oncotarget. 2014;5(20):9546-9563.
Wu, Xiaoliang ; Liu, Xuewen ; Koul, Sanjay ; Lee, Chang Youl ; Zhang, Zhenfeng ; Halmos, Balazs. / AXL kinase as a novel target for cancer therapy. In: Oncotarget. 2014 ; Vol. 5, No. 20. pp. 9546-9563.
@article{7cce804e317b457fb3ab373969e05182,
title = "AXL kinase as a novel target for cancer therapy",
abstract = "The AXL receptor tyrosine kinase and its major ligand, GAS6 have been demonstrated to be overexpressed and activated in many human cancers (such as lung, breast, and pancreatic cancer) and have been correlated with poor prognosis, promotion of increased invasiveness/metastasis, the EMT phenotype and drug resistance. Targeting AXL in different model systems with specific small molecule kinase inhibitors or antibodies alone or in combination with other drugs can lead to inactivation of AXL-mediated signaling pathways and can lead to regained drug sensitivity and improved therapeutic efficacy, defining AXL as a promising novel target for cancer therapeutics. This review highlights the data supporting AXL as a novel treatment candidate in a variety of cancers as well as the current status of drug development targeting the AXL/GAS6 axis and future perspectives in this emerging field.",
keywords = "Axl, Lung cancer, Receptor tyrosine kinase, Targeted therapy",
author = "Xiaoliang Wu and Xuewen Liu and Sanjay Koul and Lee, {Chang Youl} and Zhenfeng Zhang and Balazs Halmos",
year = "2014",
language = "English (US)",
volume = "5",
pages = "9546--9563",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "20",

}

TY - JOUR

T1 - AXL kinase as a novel target for cancer therapy

AU - Wu, Xiaoliang

AU - Liu, Xuewen

AU - Koul, Sanjay

AU - Lee, Chang Youl

AU - Zhang, Zhenfeng

AU - Halmos, Balazs

PY - 2014

Y1 - 2014

N2 - The AXL receptor tyrosine kinase and its major ligand, GAS6 have been demonstrated to be overexpressed and activated in many human cancers (such as lung, breast, and pancreatic cancer) and have been correlated with poor prognosis, promotion of increased invasiveness/metastasis, the EMT phenotype and drug resistance. Targeting AXL in different model systems with specific small molecule kinase inhibitors or antibodies alone or in combination with other drugs can lead to inactivation of AXL-mediated signaling pathways and can lead to regained drug sensitivity and improved therapeutic efficacy, defining AXL as a promising novel target for cancer therapeutics. This review highlights the data supporting AXL as a novel treatment candidate in a variety of cancers as well as the current status of drug development targeting the AXL/GAS6 axis and future perspectives in this emerging field.

AB - The AXL receptor tyrosine kinase and its major ligand, GAS6 have been demonstrated to be overexpressed and activated in many human cancers (such as lung, breast, and pancreatic cancer) and have been correlated with poor prognosis, promotion of increased invasiveness/metastasis, the EMT phenotype and drug resistance. Targeting AXL in different model systems with specific small molecule kinase inhibitors or antibodies alone or in combination with other drugs can lead to inactivation of AXL-mediated signaling pathways and can lead to regained drug sensitivity and improved therapeutic efficacy, defining AXL as a promising novel target for cancer therapeutics. This review highlights the data supporting AXL as a novel treatment candidate in a variety of cancers as well as the current status of drug development targeting the AXL/GAS6 axis and future perspectives in this emerging field.

KW - Axl

KW - Lung cancer

KW - Receptor tyrosine kinase

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84922744761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922744761&partnerID=8YFLogxK

M3 - Article

C2 - 25337673

AN - SCOPUS:84922744761

VL - 5

SP - 9546

EP - 9563

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 20

ER -